According to the news from chinastarmarket.cn on the 31st, the domestic vaccine leader, AIM Vaccine, released a morning notice that its candidate of EV71-CA16 bivalent HFMD vaccine (human diploid cell) recently obtained clinical approval from CDE. According to public information, currently approved HFMD vaccines in China are all inactivated EV71 vaccines which are only effective against the EV71 strain. There is still no bivalent HFMD vaccine targeting both EV71 and CA16 strains. The clinical approval of the EV71-CA16 bivalent HFMD vaccine (human diploid cell) is expected to fill this gap. AIM Vaccine has been reported of several R&D milestones since October. Apart from the aforementioned bivalent HFMD vaccine, another major innovative vaccine of AIM Vaccine, serum-free rabies vaccine (Vero cell), also obtained clinical approval recently.